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Abstract: The renin angiotensin system (RAAS) plays an important role in the pathophysiology 
of cardiovascular (CV) disease. Modulation of RAAS with angiotensin-converting enzyme 
inhibitors (ACEi), angiotensin receptor blockers (ARB), and aldosterone inhibitors reduces 
a range of adverse CV outcomes in patients with or at risk of CV disease. Currently, there is 
incomplete evidence to show all RAAS modulators provide vascular protection by reducing 
the incidence of myocardial infarction (MI), stroke and CV death. In patients at high risk for 
CV events, studies with ACEi designed to test for long-term vascular protection, showed ben-
eﬁ  t. In contrast, studies of ARBs in patients with hypertension, heart failure, and renal disease 
have not consistently shown a reduction of CV outcomes. However, none of these studies was 
speciﬁ  cally designed to examine the impact of ARBs on the vascular protective outcomes of 
CV death, non-fatal MI, and stroke. The ONTARGET and TRANSCEND studies are designed 
to determine whether the ARB telmisartan is similar (or non-inferior) or superior to the ACEi 
ramipril in the reduction of CV events in patients with established CV disease or diabetes with 
target organ damage. The ONTARGET study has enrolled 25,620, and TRANSCEND 5,776 
subjects. The subjects in both trials are similar to those studied in the HOPE study, yet there 
is greater ethnic diversity, a higher proportion of patients with cerebro-vascular disease, and a 
greater use of beta blockers and lipid-lowering treatment. The studies completed recruitment 
in 2004, and are due to complete follow-up and report the results in 2008. The ONTARGET 
and TRANSCEND studies will provide valuable comparative data on the efﬁ  cacy of telmis-
artan and ramipril and their combination in patients at high risk for CV events. Although it is 
possible that enhanced beneﬁ  ts will be observed with dual therapy, the outcomes with ARB 
monotherapy remain uncertain.
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Role of angiotensin in the pathophysiology 
of cardiovascular disease
The renin angiotensin aldosterone system (RAAS) plays an important role in the devel-
opment of cardiovascular (CV) disease. RAAS is a mediator for the development of 
atherosclerosis and atherothrombotic complications (Dzau 2001). In addition, RAAS 
activation promotes adverse remodeling of the damaged heart and the subsequent 
development of heart failure (Dzau 2005). Angiotensin II mediated stimulation of 
the AT1 receptor increases arterial pressure, promotes oxidative stress, stimulates 
an inﬂ  ammatory response, and adversely alters the balance between the thrombotic 
and ﬁ  brinolytic state (Wagenaar et al 2002). AT1 receptors are upregulated in both 
experimental models and in patients with hypercholesterolemia (Strehlow et al 2000), 
thus enhancing the atherogenic state associated with hyperlipidemia.
Modulation of RAAS with either angiotensin-converting enzyme inhibitors (ACEi) 
or with AT1 receptors blockers (ARB) restrains several of the pathological processes 
that contribute to atherosclerosis and atherothrombosis (Dzau 1998). Blockade of the Vascular Health and Risk Management 2007:3(6) 902
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AT1 receptor reduces activation of pathways associated with 
the development of oxidative stress, diminishing activation 
of inﬂ  ammatory cells, including monocyte migration and 
adhesion to endothelial cells (Grafe et al 1997; Dol et al 
2001). In addition, both ACEi and ARBs have been shown to 
alter factors that promote ﬁ  brinolysis and reduce thrombosis 
(Vaughan 2001). ARBs, on the other hand might be pro-
thrombotic by stimulating PAI-1 synthesis (Brown et al 2002) 
and encourage plaque rupture by enhancing MMP-1 activity 
(Kim et al 2005). Thus, experimental evidence suggests the 
both ACEi and the ARB classes of RAAS modulators have 
beneﬁ  cial properties, which may reduce the development 
of atherosclerosis and its complications. Yet for the ARBs, 
vascular protective beneﬁ  ts remain uncertain until tested in 
a clinical trial.
Clinical trials in renin angiotensin 
system modulation and vascular 
protection
Angiotensin converting enzyme inhibition
The ACEi were initially introduced into the clinical arena for 
blood pressure control and management of heart failure. The 
SAVE (Pfeffer et al 1992) and SOLVD (The SOLVD Inves-
tigators 1992) trials of captopril and enalapril in patients with 
heart failure showed an important reduction of CV mortality 
and the progression of heart failure. Both of these heart failure 
trials observed that treatment with ACEi was associated 
with a 20%–25% reduction in the incidence of non-fatal 
myocardial infarction (MI) (Rutherford et al 1994). These 
observations lead to the HOPE trial (Yusuf et al 2000) in 
which high dose ACEi with ramipril 10 mg daily reduced the 
risk of MI by 20%, stroke by 32%, and CV mortality by 26% 
in patients at high risk for CV events but without heart failure 
or a low left ventricular ejection fraction. Subsequently the 
EUROPA study (The EURopean trial On reduction of cardiac 
events with Perindopril in stable coronary Artery disease 
Investigators 2003) showed that perindopril 8 mg daily in 
patients with coronary artery disease reduced the endpoint 
of CV mortality, non-fatal MI, and cardiac arrest by 20%. 
Non-fatal MI was signiﬁ  cantly reduced 22%, yet there were 
insufﬁ  cient events to show a statistically signiﬁ  cant reduction 
of CV mortality.
In contrast the PEACE trial (The PEACE Investigators 
2004) failed to show a beneﬁ  t from treatment with trandol-
april 4 mg daily in patients with coronary artery disease. The 
study population was at low risk of CV events and the trial 
underpowered to show a beneﬁ  t from the ACEi treatment. 
Coronary revascularization was the major contributor to 
the combined endpoint and occurred at similar rates in both 
treatment arms. In contemporary North American practice, 
aggressive coronary revascularization is probably a non-
modiﬁ  able endpoint, as it is widely used independent of 
ischemia driven indications.
A combined analysis of the HOPE, EUROPA, and PEACE 
trials (Dagenais et al 2006) showed that ACEi signiﬁ  cantly 
reduced all cause mortality (7.8 vs 8.9% p = 0.0004), CV 
mortality (4.3 vs 5.2% p = 0.0002), non-fatal MI (5.3 vs 6.4% 
p = 0.0001), stroke (2.2 vs 2.8% p = 0.0004), coronary artery 
bypass surgery (6.0 vs 6.9%), but not percutaneous coronary 
intervention (7.4 vs 7.6% p = 0.48). Similar reductions of CV 
mortality and MI are observed in the ﬁ  ve trials in patients with 
heart failure or left ventricular systolic dysfunction (Danchin 
et al 2006).
The contribution of ACEi induced blood pressure reduc-
tion to the improved vascular outcomes remains controver-
sial. In the HOPE study the average systolic and diastolic 
blood pressure reductions were 3/2 mmHg and in EUROPA 
5/2 mmHg. Although blood pressure reduction may play a 
role, a high proportion of patients in both studies were nor-
motensive and still received beneﬁ  t from ACEi. Furthermore 
recent meta-regression analyses indicate that outcomes in 
patients receiving ACEi are better than would be expected 
from blood pressure lowering alone (Verdecchia et al 2005). 
A recent meta-regression analysis from the Blood Pressure 
Lowering Trialists with 140,000 subjects compared ACEi 
and ARB trials (Turnbull et al 2005). The study suggested 
that ACEi had a 9% greater effect on the reduction of MI 
and CV death, and beneﬁ  ts independent of blood pressure 
reduction. Similar blood pressure-independent effects of 
ARBs were not observed.
As a consequence of the HOPE and EUROPA stud-
ies, guidelines for the management of MI, heart failure 
hypertension, and diabetes recommend that ACEi should 
be considered in patients at a very high risk for recurrent 
vascular events.
Angiotensin receptor blockade
ARBs offer more effective interruption of the effects of 
angiotensin II on the AT1 receptor than ACEi. Current clini-
cal trials indicate that for blood pressure control, prevention 
of heart failure mortality and morbidity, and retardation of the 
progression of diabetic nephropathy, ARBs appear to be as 
effective as ACEi. However, there is currently only limited 
evidence to show that ARBs reduce the incidence of MI. 
The ONTARGET and TRANSCEND studies will be the ﬁ  rst Vascular Health and Risk Management 2007:3(6) 903
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to examine directly the vascular protective properties of 
ARBs used alone or in combination with ACEi.
Do the existing clinical trials suggest that ARBs have 
vascular protective properties similar to those demonstrated 
with ACEi? In contrast to the placebo-controlled ACEi trials 
described above, most ARB clinical trials have compared the 
ARB with another medication. In heart failure trials, the com-
parator was usually an ACEi, whereas in hypertension trials 
the ARB was compared with other medication strategies. The 
placebo-controlled clinical trials with clinical outcomes are 
either in ACEi intolerant patients (CHARM alternative) or in 
patients with diabetic nephropathy (RENAAL and IDNT).
ARBs are probably as effective as ACE inhibitors in 
reducing heart failure mortality (Pfeffer et al 2003b). Fur-
thermore the combination of the ARB candesartan with an 
ACE inhibitor in the CHARM Added trial was associated 
with a 17% reduction of both CV mortality and admission 
to hospital for heart failure (McMurray et al 2003). In the 
CHARM overall trial (Demers et al 2004), patients receiving 
candesartan had a 23% reduction (95% CI 2%–40%) of non-
fatal MI as well as a 12% reduction (95% CI 13%–21%) of 
CV death. The reduction of MI with candesartan was similar 
in patients receiving and not receiving an ACEi. Yet in the 
CHARM Alternative trial (Granger et al 2003) where can-
desartan was compared with placebo in patients intolerant 
of ACEi, there was a statistically signiﬁ  cant 52% increase 
in the incidence of MI for patients receiving candesartan 
compared with those receiving placebo. However, the risk 
of CV death was decreased by 20% (p = 0.02 after covariate 
adjustment).
ARBs are effective and well tolerated antihypertensive 
agents. The LIFE trial (Dahlof et al 2002) showed the ARB 
losartan compared with atenolol resulted in a greater reduc-
tion of the combined end-point of CV death, MI, or stroke 
after equal blood pressure control, for the management of 
the older patient with moderately severe hypertension and 
left ventricular hypertrophy. For the individual components 
of the primary endpoint, losartan reduced stroke, but there 
was no impact on either CV mortality or MI. In patients with 
diabetes, losartan reduced CV and total mortality, but not MI. 
Furthermore, atenolol is not the optimal antihypertensive 
comparator in an older population, as a recent meta-analysis 
showed a higher mortality with atenolol than with other anti-
hypertensive medications (Carlberg et al 2004).
In the VALUE trial (Julius et al 2004), valsartan was not 
as effective as an antihypertensive agent as amlodipine, yet 
there was no difference in the primary combined endpoint of 
CV mortality and morbidity. Acute vascular events (MI and 
CVA) were less frequent in the amlodipine-treated patients. 
It seems unlikely that a 2–4 mmHg higher systolic blood 
pressure in the valsartan-treated patients during the ﬁ  rst few 
months of treatment could account for a 19% increase in MI 
(p = 0.02) and 15% (p = 0.08) increase in stroke throughout 
the course of the trial.
Following acute MI, the major threat to survival and 
future morbidity is from recurrent acute coronary events, the 
development of heart failure and life threatening arrhythmias. 
ACE inhibition reduces the risk of death by 26%, major 
non-fatal CV events such as hospital admission for heart 
failure by 27%, and recurrent MI by 20% (Flather et al 
2000). The VALIANT (Pfeffer et al 2003a) trial showed the 
ARB valsartan was not inferior to captopril in the reduction 
of all-cause mortality in patients with heart failure or left 
ventricular ejection fraction <40%. MI rates were similar in 
the valsartan- and captopril-treated patients.
The diabetic patient with micro- or macroalbuminuria is 
at a high risk for adverse CV outcomes. Although the dia-
betic nephropathy trials RENAAL (Brenner et al 2001) and 
IDNT (Parving et al 2001) did not have CV events as primary 
outcomes, it is possible to gain some insight of the value of 
ARBs relative to placebo in such a high risk population. Both 
trials showed that the ARB successfully slowed the progres-
sion of renal failure. An analysis of the CV outcomes in the 
IDNT trial (Berl et al 2003) also showed that congestive heart 
failure was less frequent in the irbesartan compared with 
placebo or amlodipine-treated patients. However, there was 
no reduction of CV mortality, MI, cardiac revascularization, 
or stroke rates in the irbesartan group. Yet there was a strong 
trend to less MI for patients receiving amlodipine compared 
with those randomized to placebo or irbesartan.
In the RENAAL trial (Brenner et al 2001), there was 
a trend towards less non-fatal MI for patients receiving 
losartan (relative risk reduction [RRR] 28% p < 0.08). The 
number of patients requiring at least one admission for heart 
failure was signiﬁ  cantly reduced in the losartan group (RRR 
32% p = 0.005). ARBs prevent the progression of diabetic 
nephropathy and reduce the combined endpoint of total mor-
tality and progression to end-stage renal failure. Yet the ARB 
nephropathy trials do not show any signiﬁ  cant reduction of 
CV events with the exception of heart failure admissions. As 
many more patients have CV events than progress to dialysis-
dependent renal failure, it is surprising that the ARB-treated 
patients did not have a reduction of CV events.
A recent discussion paper (Strauss and Hall 2006) has 
suggested that ARBs may increase the incidence of MI. 
This hypothesis, supported by a meta-analysis of over Vascular Health and Risk Management 2007:3(6) 904
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50,000 patients in clinical trials that compared ARBs with 
placebo, non-ACEi comparators and ACEi suggested 
there was a signiﬁ  cant 8% increase in MI for ARB-treated 
patients compared with the comparator. An alternative 
explanation is that the comparators that included ACEi and 
beta-adrenergic blockers had a more powerful effect than 
the ARB in reducing coronary events. Only a randomized 
trial such as ONTARGET and TRANSCEND will answer 
this controversy.
Potential differences between the 
effects of ACEi inhibitors and ARB
ACE inhibition reduces angiotensin II available to 
stimulate the AT receptors. Alternative pathways for 
AII synthesis, as mediated by other proteolytic enzyme 
such as chymase, explain the failure of ACEi to reduce 
circulating AII during long-term treatment. However, in 
tissues, different mechanisms for AII synthesis may be in 
play, as ACE and not chymase co-localizes with angiotensin 
II (Ohishi M et al 1999) in atherosclerotic plaque. Conse-
quently, it is possible there is no breakthrough synthesis of 
angiotensin II in the atherosclerotic plaque in the presence 
of an effective ACEi. ACE not only promotes the synthesis 
of angiotensin II, but the same enzyme also inactivates the 
vasoactive peptide bradykinin and inhibition of ACE with 
ACEi increases the availability of bradykinin (Hornig et al 
1997). Bradykinin is not only a vasodilator peptide, but is 
also a powerful stimulant of endothelial nitric oxide syn-
thesis which inhibits cell proliferation and an inﬂ  ammatory 
response (Murphey et al 2003). Bradykinin restores a favor-
able ﬁ  brinolytic balance by stimulating the synthesis of tissue 
plasminogen activator (tPA) (Vaughan 2001).
Long-term AT1 inhibition results in a several-fold 
increase in plasma angiotensin II and the unopposed 
stimulation of AT2 receptors (Horiuchi et al 1999). Early 
studies suggested that stimulation of the AT2 receptor was 
beneﬁ  cial, with effects that counterbalanced the effects of 
AT1 stimulation (Matsubara 1998). Consequently, unop-
posed AT2 stimulation was considered to be one of the 
potential beneﬁ  ts of interruption of the effects of angiotensin 
II with an ARB. Yet recent research has not only questioned 
the role of the AT2 receptor in adult human vasculature, but 
also suggested that AT2 over-stimulation may be detrimental. 
Levy, in a recent review (Levy 2004), suggested that AT2 
stimulation can in certain situations result in cellular prolif-
eration, an increase in ﬁ  brosis, inappropriate apoptosis and an 
associated anti-angiogenic effect: all effects that might result 
in increased atherogenesis and a poor outcome following 
vascular occlusion. Clearly, the biology of AT2 receptors is 
much more complex than we had previously believed, and 
there is insufﬁ  cient evidence to show AT2 receptor stimula-
tion during ARB therapy is equivalent to the effects of ACEi 
on bradykinin and nitric oxide.
Both the ACEi and the ARB class of agents have 
properties that would be expected to reduce CV events. 
However, both the ACEi and ARBs have limitations that 
might translate into a smaller beneﬁ  t than might be predicted 
from their effect on RAAS modulation. Hence, the need 
for a clinical trial to explore the beneﬁ  ts of each agent and 
in combination for patients at high risk of CV mortality, 
MI, and stroke.
The ONTARGET and   TRANSCEND 
trials
The Ongoing Telmisartan Alone and in Combination 
with Ramipril Global Endpoint Trial (ONTARGET) and 
Telmisartan Randomized Assessment Study in ACE Intoler-
ant Subjects with Cardiovascular Disease (TRANSCEND) 
trials will examine the role of ARBs when used alone or 
in combination with an ACEi in high risk individuals with 
controlled hypertension (Teo et al 2004). The primary 
objective of the ONTARGET trial is to determine whether 
the combination of telmisartan 80 mg (Micardis®, Boehringer 
Ingelheim) and ramipril 10 mg (Altace®, Sanoﬁ  -Aventis, 
King) is more effective than ramipril alone and to assess 
whether telmisartan alone is at least as effective as ramipril. 
The TRANSCEND trial will determine whether telmisartan 
80 mg reduces vascular endpoints compared with placebo in 
patients intolerant of ACEi. The dose of ramipril is the dose 
shown to have vascular protective beneﬁ  t in the HOPE study 
(Yusuf et al 2000). The telmisartan dose is the dose that is 
effective and well tolerated in hypertensive trials. The primary 
endpoint for both trials is the combination of CV death, non-
fatal MI, stroke, or hospitalization for heart failure. The two 
studies included patients at high risk for coronary, peripheral or 
cerebrovascular events as summarized in Table 1. Recruitment 
from 730 centres in 40 countries for ONTARGET (n = 25,620) 
was completed in July 2003, and TRANSCEND (n = 6,000) in 
May 2004. The study results will be reported in 2008.
The study design is shown in Figure 1. After evaluation for 
eligibility, subjects entered a 3-week run-in period receiving 
open label study drugs in escalating doses. Patients who 
were adherent to and tolerated the study medication were 
randomized to the treatment groups as shown in Figure 1. During 
the follow-up period of 3.5–5.5 years, events comprising 
the primary, secondary, and other outcomes are recorded Vascular Health and Risk Management 2007:3(6) 905
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and conﬁ  rmed by a central adjudicator. The study has an 
89% power of showing the non-inferiority of telmisartan 
compared with ramipril that ensures telmisartan has at least 
50% of the ramipril effect at the upper 95th% conﬁ  dence 
limit.
The study is designed to have a 93% power of showing a 
13% superiority of telmisartan plus ramipril vs ramipril alone. 
However, a non-inferiority analysis will be performed initially 
prior to an analysis for superiority. In the TRANSCEND study 
with 3,000 patients in each group the study has a 94% power 
to show a 19% superiority of telmisartan over placebo.
Baseline characteristics in ONTARGET 
and TRANSCEND: a comparison with 
HOPE
The major baseline characteristics of the ONTARGET and 
TRANSCEND studies compared with those from the HOPE 
study are shown in Table 2. A complete list is available in 
the design and baseline characteristics publication (Teo 
et al 2004). The age of the patients in the ONTARGET and 
TRANSCEND studies is slightly older than in the HOPE 
trial. A greater proportion of female subjects are entered into 
the TRANSCEND trial than was seen in either ONTARGET 
or HOPE. A similar  higher proportion of female subjects 
(31.8%) was observed in the ACEi intolerant arm of the 
CHARM study compared with the 21.2% in the overall 
CHARM trial. Diabetes was present at a similar prevalence 
in the ONTARGET and TRANSCEND studies as in HOPE. 
In the current trials the use of ACEi and statins prior to 
enrollment was considerably greater than reported in HOPE. 
Blood pressures in the ONTARGET and TRANSCEND 
patients are slightly higher than in HOPE at the time of 
initial assessment.
What can we expect from the 
ONTARGET and TRANSCEND 
trials
Placebo-controlled clinical trials have shown that long-term 
treatment with ACE inhibition is effective for the manage-
ment of disease across the CV continuum (Table 3). ARBs 
are as effective as ACEi in the management of heart failure, 
and left ventricular systolic dysfunction after MI. Although 
Table 1 Inclusion and exclusion criteria for ONTARGET and TRANSCEND trials
Inclusion criteria
Individuals  55 years of age with one of the following:
Coronary artery disease  Prior AMI ( 2 days post uncomplicated AMI)
  Stable angina
  Unstable angina ( 30 days before + documented CAD)
  Multivessel PCI ( 0 days before)
  Multivessel CABG ( 4 years before or with recurrent angina)
Peripheral artery disease  Prior limb vascular surgery or angioplasty
  Limb/foot amputation
  Intermittent claudication (ABIa   0.80)
  Signiﬁ  cant peripheral vascular stenosis ( 50%) by angiography
Cerebrovascular disease  Previous stroke
  TIA after  7 days and  1 year
Diabetes mellitus  High risk patient with evidence of end organ damage
Exclusion criteria
Medication use  Inability to discontinue ACEi or ARB
  Known hypersensitivity or intolerance to ARB or ACEi (except 
  TRANSCEND)
CVD  Symptomatic heart failure
  Signiﬁ  cant valvular heart disease
  Pericardial constriction
  Complex congenital heart disease
  Syncopal episodes of unknown aetiology
  Planned PCI or CABG   3 months after randomization
  Uncontrolled hypertension (BP  160/100)
  Heart transplant recipient
  Stroke due to subarachnoid hemorrhage
Others (examples)  Signiﬁ  cant renal disease
  Proteinuria (TRANSCEND only)
  Hepatic dysfunction
aAnkle brachial index.Vascular Health and Risk Management 2007:3(6) 906
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ACEi prevent acute MI in patients with and without systolic 
dysfunction, it remains controversial whether ARBs have 
similar vascular protective beneﬁ  ts.
There are several possible scenarios. Firstly the effect of 
the combination of ACE inhibitor and ARB is likely to show 
enhanced beneﬁ  ts for the primary outcome compared with 
monotherapy. An ACEi and ARB combination in patients 
with heart failure in the Randomized Evaluation of Strategies 
for Left Ventricular Dysfunction (RESOLVD) (McKelvie 
et al 1999) showed that the combination of enalapril and 
candesartan resulted in signiﬁ  cantly lower systolic and 
diastolic blood pressures compared with either medication 
alone. In addition, combined ACEi ARB therapy further 
reduced neurohormone levels and improved cardiac function. 
Consequently, it is likely that the combined treatment will 
reduce vascular and heart failure endpoints more than either 
ramipril or telmisartan as monotherapy. How much of the 
beneﬁ  t will be from greater blood pressure lowering and 
how much from non-BP lowering effects will be difﬁ  cult 
to assess.
Tolerate ACEi 
ONTARGET 
N=23,400
TRANSCEND 
N=6,000
Yes No
Telmisartan 80 mg 
+ Ramipril 10 mg 
N=7,800 
Ramipril 10 mg 
N=7,800 
Placebo
N=3,000 
Telmisartan 80 mg
N=3,000 
Composite of CV death, non-fatal MI, non-fatal
stroke, or hospitalization for heart failure  
Newly diagnosed heart failure, revascularization
procedures, newly diagnosed diabetes, development
of dementia, nephropathy, and atrial fibrillation   
All cause mortality, non-CV death, TIAs,
development of LVH, microvascular complications
of diabetes, changes in BP and ABI
a, malignancy   
Primary 
Outcome 
Secondary
Outcomes 
Other
Outcomes 
Telmisartan 80 mg 
N=7,800 
Follow-up of 3.5-5.5 years 
High risk patients >55 years old with previous vascular events
 or diabetes with target organ damage  
Figure 1 ONTARGET and TRANSCEND study designs. aAnkle brachial index.Vascular Health and Risk Management 2007:3(6) 907
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Table 2 Baseline characteristics in ONTARGET,  TRANSCEND 
and HOPE trials
 ONTARGET  TRANSCEND  HOPE
Age (y)  66.4  66.9  65.9
Male (%)  73.3  57.1  73.3
Prior MI (%)  48.7  46.2  52.8
BMI   28.2  28.3  27.2
Revascularization (%)     
 PCI  28.9  26.0  18.0
 CABG  22.1  18.9  26.0
Risk factors (%)     
Hypertension 68.3  75.9  46.5
Diabetes 37.3  35.4 38.3
Current smoker  12.5  9.8  14.1
Medication (%)     
ACEi 57.5  58.1  11.6
ARB 8.6  29.9  –
Statins 60.7  54.5  28.9
BP at run-in  143/82  142/82  139/79
Adapted from Teo et al (2004).
The comparison between the ACEi ramipril with the 
ARB telmisartan is designed to show non-inferiority of 
telmisartan. In other words, is “most” of ramipril’s effect 
vs placebo preserved by telmisartan? In ONTARGET, the 
non-inferiority margins for the comparison have been set 
to assure that telmisartan retains at least half of the ramipril 
effect. Thus if telmisartan has vascular protective proper-
ties, it is likely that it will be shown to be non-inferior to 
ramipril.
For the comparison of telmisartan with placebo in ACEi-
intolerant patients in TRANSCEND, the study is powered 
to show a 19% reduction of event rates. As event rates of 
patients with vascular disease have been reduced by a more 
aggressive approach vascular protection with the greater 
use of statins revascularization and lifestyle measures, it 
is possible that the event rates in the ONTARGET and 
TRANSCEND population will be below the 3.97% observed 
in HOPE. If the event rates are low, it is likely that the 
TRANSCEND study, with a total of 6,000 patients, will be 
underpowered to show a beneﬁ  t for telmisartan.
Class effect of ARBs or beneﬁ  t from 
only telmisartan
Should the ARB telmisartan be shown to be non-inferior or 
superior to the ACEi ramipril, are the results generalizable 
to all ARBs or are they a speciﬁ  c beneﬁ  t of the ARB telmis-
artan? Telmisartan has a longer half-life than other ARBs. 
Consequently, once-daily treatment results in blood pressure 
lowering throughout the next 24 hours after receiving the 
medication.  Recent pre-clinical studies have suggested that 
telmisartan may have properties associated with vascular 
protection beyond those achievable with angiotensin recep-
tor blockade alone (Kurtz and Pravenek 2004). Telmisartan 
acts as a selective partial agonist of peroxisome proliferator-
activated receptor-gamma (PPAR-γ ). This nuclear receptor 
inﬂ  uences the expression of multiple genes involved in lipid 
and carbohydrate metabolism. PPAR-γ  is therefore a poten-
tial therapeutic target for modulation of insulin resistance, 
treatment of diabetes, and prevention of atherosclerosis. In 
clinical studies (DeRosa et al 2004) telmisartan improved 
carbohydrate and lipid metabolism without the side effects 
associated with the full PPAR-γ activators such as the 
thiazolidinediones (TZDs). With more effective 24-hour 
blood pressure lowering and different pleiotropic effects, 
any observed beneﬁ  ts of telmisartan may not be generaliz-
able to the other ARBs. Furthermore the effective vascular 
protective dose of other ARBs would be no more than an 
intelligent guess.
Conclusion
The ONTARGET and TRANSCEND studies will provide 
important information to support or refute the hypothesis 
that ARBs have similar vascular protective properties as 
the ACEi. ARBs are generally tolerated better than ACEi. 
Consequently should the ONTARGET and TRANSCEND 
studies show the non-inferiority of telmisartan to ramipril, it 
is likely that telmisartan, the ARB with evidence, will become 
the favored treatment for vascular protection.
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